66 results
Search Results
2. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications.
- Author
-
Seida, Isa, Alrais, Mahmoud, Seida, Ravend, Alwani, Abdulkarim, Kiyak, Zeynep, Elsalti, Abdulrahman, Nil Esirgun, Sevval, Abali, Tunahan, and Mahroum, Naim
- Subjects
COVID-19 pandemic ,VACCINE manufacturing ,SYSTEMIC lupus erythematosus ,AUTOIMMUNE diseases ,MINERAL oils ,SYNDROMES ,ANTIPHOSPHOLIPID syndrome - Abstract
Summary: Adjuvants, as the name indicates, are adjoined material aimed to assist in functioning as when added to vaccines they are meant to boost the effect and strongly stimulate the immune system. The response of the immune system can be unpredictable, and the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) was developed to address possible adverse reactions of an autoimmune and inflammatory type that may be caused by adjuvants. While ASIA, as a syndrome, was coined and defined in 2011; reports describing patients with vague and nonspecific clinical symptoms following vaccinations appeared much earlier. In other words, ASIA came to define, arrange, and unite the variety of symptoms, related to autoimmunity, caused not by the vaccine itself, rather by the adjuvant part of the vaccine such as aluminum, among others. Accordingly, the introduction of ASIA enabled better understanding, proper diagnosis, and early treatment of the disorder. Furthermore, ASIA was shown to be associated with almost all body systems and various rheumatic and autoimmune diseases such as systemic lupus erythematosus, antiphospholipid syndrome, and systemic sclerosis. In addition, the correlation between COVID-19 and ASIA was noticed during the pandemic. In this review, we summarized the reported effects of adjuvants and medical literature before and after ASIA was defined, the several ways ASIA can manifest and impact different systems of the body, and the incidences of ASIA during the COVID-19 pandemic. It is important to clarify, that vaccines are among, if not the, most effective means of fighting infectious diseases however, we believe that vaccines manufacturing is not above criticism, particularly when it comes to added substances possessing a risk of side effects. Adjuvants such as aluminum, mineral oils, and silicone are added to vaccines in order to trigger a stronger immune response. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) was introduced in 2011 to address nonspecific symptoms and disorders appearing following vaccinations, which in fact were reported by many papers before the introduction of the syndrome. During the pandemic of COVID-19, a correlation between ASIA, COVID-19, and COVID-19 vaccines has been reported. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events.
- Author
-
Farina, Nicola, Abdulsalam, Ruya, McDonnell, Thomas, Pericleous, Charis, D'Souza, Amrita, Ripoll, Vera M, Webster, Jemma, Isenberg, David A, Giles, Ian, and Rahman, Anisur
- Subjects
THROMBOSIS ,ANTIPHOSPHOLIPID syndrome ,RESEARCH funding ,ENZYME-linked immunosorbent assay ,KAPLAN-Meier estimator ,SURVIVAL analysis (Biometry) ,GLYCOPROTEINS ,SYSTEMIC lupus erythematosus ,VASCULAR diseases ,PHOSPHOLIPIDS - Abstract
Objective aPL are found in the blood of 20–30% of patients with SLE. Although aPL cause vascular thrombosis in the antiphospholipid syndrome, it is not clear whether positive aPL levels in early SLE increase risk of subsequent vascular events (VE). In a previous analysis of 276 patients with SLE, we found that early positivity for ≥2 of IgG anti-cardiolipin (anti-CL), IgG anti-β
2 -glycoprotein I (anti-β2GPI) and anti-domain I of β2 -glycoprotein I (anti-DI) showed a possible association with VE. Here we have extended that analysis. Methods Serum samples taken from 501 patients with SLE early in their disease had been tested for IgG anti-CL, anti-β2GPI and anti-DI by ELISA. Complete VE history was available for 423 patients of whom 23 were excluded because VE occurred before the diagnosis of SLE. For the remaining 400 patients we carried out Kaplan–Meier survival analysis to define groups at higher risk of VE. Results Of 400 patients, 154 (38.5%) were positive for one or more aPL, 27 (6.8%) were double/triple-positive and 127 (31.8%) were single-positive. There were 91 VE in 77 patients, of whom 42 were aPL-positive in early disease. VE were significantly increased in aPL-positive vs aPL-negative patients (P = 0.041) and in double/triple-positive vs single-positive vs aPL-negative patients (P = 0.0057). Omission of the IgG anti-DI assay would have missed 14 double/triple-positive patients of whom six had VE. Conclusion Double/triple-positivity for IgG anti-CL, anti-β2GPI and anti-DI in early SLE identifies a population at higher risk of subsequent VE. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
4. Cerebrovascular disease in patients with antiphospholipid antibody syndrome: a transcranial Doppler and magnetic resonance imaging study.
- Author
-
Ricarte, Irapuá Ferreira, Dutra, Lívia Almeida, Rodrigues, Daniela Laranja Gomes, Barsottini, Orlando Graziani Povoas, Souza, Alexandre Wagner de, Carrete, Henrique, Massaud, Ana Paula Scalzaretto, Andrade, Danieli, Mangueira, Cristóvão Luís Pitangueira, and Silva, Gisele Sampaio
- Subjects
CEREBROVASCULAR disease ,PHOSPHOLIPID antibodies ,MAGNETIC resonance imaging - Abstract
Objective Transcranial Doppler (TCD) and brain MRI may be useful in evaluating patients with APS, helping to stratify the risk of cerebrovascular ischaemic events in this population. This study aimed to assess the frequency of brain MRI abnormalities in patients with primary antiphospholipid syndrome, secondary antiphospholipid syndrome and SLE and correlate to TCD findings. Methods The study, conducted over four years at two autoimmune disease referral centres, included 22 primary antiphospholipid syndrome patients, 24 secondary antiphospholipid syndrome patients, 27 SLE patients without APS and 21 healthy controls. All participants underwent TCD to assess cerebral haemodynamics, detect microembolic signals and evaluate right-to-left shunts, followed by brain MRI and magnetic resonance angiography. MRI scans were reviewed for acute microembolism, localized cortical infarctions, border infarctions, lacunar infarctions, ischaemic lesions, white matter hyperintensity, micro and macro haemorrhages and arterial stenosis ≥50% of the cervical carotid artery, by two neuroradiologists blinded to the clinical data. Results Brain MRI findings were similar between the groups, except for lacunar infarction, more frequent in patients with secondary antiphospholipid syndrome (P = 0.022). Patients with intracranial stenosis detected by TCD had a higher frequency of territorial infarction (40% vs 7.5%, P = 0.02), lacunar (40% vs 11.3%, P = 0.075) and border zone infarcts (20% vs 1.9%, P = 0.034). Conclusions Patients with intracranial stenosis presented a higher frequency of territorial, lacunar and border zone infarcts, suggesting that evaluating the intracranial vasculature should not be neglected in patients with APS and stroke. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Hughes syndrome (the antiphospholipid syndrome): 25 years old.
- Author
-
Edwards, C. J. and Hughes, G. R. V.
- Subjects
ANTIPHOSPHOLIPID syndrome ,AUTOIMMUNE diseases ,THROMBOSIS ,IMMUNOGLOBULINS ,MISCARRIAGE - Abstract
The antiphospholipid (Hughes) syndrome (APS) is a unique thrombotic disorder, causing both arterial and venous thrombosis, linked to the presence of antibodies directed against phospholipid–protein complexes. The first papers describing the syndrome were published in 1983 and, over the next two years, a series of publications described in detail the various clinical manifestations of the syndrome. Laboratory standardisation workshops were also set up and, in 1984, the first “world” symposium on APS was held. The international APS conferences have continued to grow in numbers and in stature. The APS has already had an impact in obstetrics, in medicine, in psychiatry, and in surgery. The approximate figure of 1 in 5 is a useful guide—1 in 5 of all young strokes, 1 in 5 recurrent miscarriages, 1 in 5 DVTs. More precise data will become available in the worlds of epilepsy, migraine, Alzheimer’s, and MS. The advent of newer “biologic” immunosuppressives such as rituximab may offer help in selected cases. Intravenous immunoglobulin has proved successful, especially in the emergency setting. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
6. Comment on: Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion: reply.
- Author
-
Zen, Margherita and Doria, Andrea
- Subjects
ANTIPHOSPHOLIPID syndrome ,SEROCONVERSION ,ANTICOAGULANTS ,TREATMENT effectiveness ,DRUG therapy ,SYSTEMIC lupus erythematosus ,IMMUNOSUPPRESSIVE agents ,EVALUATION - Published
- 2021
- Full Text
- View/download PDF
7. Preclinical ocular changes in systemic lupus erythematosus patients by optical coherence tomography.
- Author
-
Pelegrín, Laura, Morató, Montse, Araújo, Olga, Figueras-Roca, Marc, Zarranz-Ventura, Javier, Adán, Alfredo, Cervera, Ricard, Casaroli-Marano, Ricardo P, Budi, Vanesa, Barrera-López, Lucía, Ríos, José, Hernández-Rodríguez, José, and Espinosa, Gerard
- Subjects
RETINAL anatomy ,CARDIOVASCULAR system physiology ,SCIENTIFIC observation ,CONFIDENCE intervals ,ANTIPHOSPHOLIPID syndrome ,CROSS-sectional method ,CASE-control method ,MANN Whitney U Test ,OPTICAL coherence tomography ,DISEASE duration ,CHI-squared test ,RESEARCH funding ,SYSTEMIC lupus erythematosus - Abstract
Objective The aim of the present study was to detect preclinical changes in SLE patients in retinal microvascularization or retinal and optical nerve structure by optical coherence tomography. Methods This cross-sectional, single-centre study aimed to describe structural changes [macular and retinal nerve fibre layer (RNFL) thickness] by structural spectral-domain optical coherence tomography (SD-OCT) and perifoveal vascular [vessel density (VD) and vascular perfusion (VP) and foveal avascular zone (FAZ) structural parameters] findings by OCT angiography (OCTA) in 78 SLE patients and 80 healthy volunteers. In addition, we analysed their association with clinical and laboratory parameters, medications received, disease duration, and SLE activity and damage. Results Structural parameters by SD-OCT and perifoveal vascular parameters by OCTA were decreased in SLE patients compared with controls. OCTA parameters (VD, VP and FAZ circularity) and macular thickness were also decreased in patients with longer disease duration (>10 years). The presence of aPLs was associated with a decreased RNFL thickness, mainly in the inferior quadrants. Patients developing APS also showed decreased RNFL thickness and OCTA flow changes. SD-OCT and OCTA results were not associated with disease activity. Foveal structural parameters were lower in patients with higher damage score. Conclusion SD-OCT and OCTA can detect preclinical structural and microcirculatory changes in SLE patients. Structural and perifoveal vascular macular changes in SLE patients are related to disease duration. Macular structural parameters were impaired in patients with higher disease damage. APS seems to be associated with preclinical damage to the optic nerve and impairment of the perifoveal microvasculature. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Erratum to: Diagnosis and treatment of patients with antiphospholipid syndrome: a mixed-method evaluation of care in The Netherlands.
- Author
-
Haneveld, Mirthe J Klein, Lemmen, Caro H C, Brunekreef, Tammo E, Bijl, Marc, Jansen, A J Gerard, Leeuw, Karina de, Spierings, Julia, Limper, Maarten, and Group, for the ARCH Study
- Subjects
ANTIPHOSPHOLIPID syndrome ,MIXED methods research - Published
- 2021
- Full Text
- View/download PDF
9. Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE.
- Author
-
Elbagir, Sahwa, Diaz-Gallo, Lina-Marcela, Grosso, Giorgia, Zickert, Agneta, Gunnarsson, Iva, Mahler, Michael, Svenungsson, Elisabet, and Rönnelid, Johan
- Subjects
THROMBOSIS risk factors ,THROMBOSIS prevention ,AUTOANTIBODIES ,THROMBOSIS ,CARDIOVASCULAR diseases risk factors ,STATISTICS ,TRIGLYCERIDES ,HLA-B27 antigen ,ANTIPHOSPHOLIPID syndrome ,MULTIVARIATE analysis ,PROTHROMBIN ,ALLELES ,RISK assessment ,COMPARATIVE studies ,RESEARCH funding ,DESCRIPTIVE statistics ,PHOSPHOLIPIDS ,SYSTEMIC lupus erythematosus ,ODDS ratio ,HIGH density lipoproteins ,LIPIDS ,DISEASE risk factors - Abstract
Objectives Emerging evidence demonstrates that aPS-PT associate with thrombotic events. Genetic predisposition, including HLA-DRB1 alleles, is known to contribute to the occurrence of conventional aPL [anti-β
2 glycoprotein-I (anti-β2 GPI) and aCL]. We investigated associations between aPS-PT and HLA-DRB1 * alleles and thrombosis in SLE. Conventional aPL were included for comparison. Methods We included 341 consecutive SLE patients, with information on general cardiovascular risk factors, including blood lipids, LA and thrombotic events. aPS/PT, anti-β2 GPI and aCL of IgA/G/M isotypes and LA were quantified. Results aPS/PT antibodies associated positively with HLA-DRB1 *13 [odds ratio (OR) 2.7, P = 0.002], whereas anti-β2 GPI and aCL antibodies associated primarily with HLA-DRB1*04 (OR 2.5, P = 0.0005). These associations remained after adjustment for age, gender and other HLA-DRB1 * alleles. HLA-DRB1*13 , but not DRB1*04 , remained as an independent risk factor for thrombosis and APS after adjustment for aPL and cardiovascular risk factors. The association between DRB1*13 and thrombosis was mediated by aPS-PT positivity. HLA-DRB1*03 , on the other hand, associated negatively with thrombotic events as well as all aPL using both uni- and multivariate analyses. HLA-DRB1*03 had a thrombo-protective effect in aPL-positive patients. Additionally, HLA-DRB1*03 was associated with a favourable lipid profile regarding high-density lipoprotein and triglycerides. Conclusions HLA-DRB1*13 confers risk for both aPS-PT and thrombotic events in lupus. The association between HLA-DRB1*13 and thrombosis is largely, but not totally, mediated through aPS-PT. HLA-DRB1*03 was negatively associated with aPL and positively with favourable lipid levels. Thus, HLA-DRB1*03 seems to identify a subgroup of SLE patients with reduced vascular risk. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
10. Major determinants of prolonged remission in systemic lupus erythematosus: retrospective study over a 41+ year period.
- Author
-
Durao-Carvalho, Goncalo, Fernández-González, Raquel, Goulden, Bethan, Farinha, Filipa, and Isenberg, David
- Subjects
MORTALITY risk factors ,SCIENTIFIC observation ,CONFIDENCE intervals ,AGE distribution ,ANTIPHOSPHOLIPID syndrome ,RETROSPECTIVE studies ,TERTIARY care ,REGRESSION analysis ,RACE ,KIDNEY diseases ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,SYSTEMIC lupus erythematosus ,WHITE people ,DISEASE remission ,PROPORTIONAL hazards models - Abstract
Objectives To investigate predictors of sustained complete remission (CR) for 3 and 5 years, minimum. Methods Retrospective observational study from January 1978 to December 2019, including systemic lupus erythmatosus (SLE) patients who attended the Lupus Clinic in a tertiary hospital, for at least 3 years. We used the BILAG score and serological profile to classify patients into CR, serologically active clinically quiescent (SACQ) and serological remission (SR). Multivariable Cox regression analysis was performed to investigate predictors of CR and Kaplan–Meier curves were obtained. Results We included 564 patients; 15% achieved CR, 7% SACQ and 15% SR. Some 63% attained no remission. In the CR group, 73% sustained the remission for 5 years or more. Patients who did not reach any kind of sustained remission died significantly earlier (P < 0.001). Cumulative survival figures at 5, 10, 20 and 30 years were 100, 100, 94 and 90%, respectively, for CR patients and 96, 93, 77 and 58%, respectively, for patients in the no-remission group. Significant predictors of CR were White ethnicity [adjusted hazard ratio (HR) 2.16 (95% CI 1.30–3.59); P = 0.003]; older age at diagnosis (>32 years) [HR 1.92 (1.24–2.97); P = 0.003]; absence of renal involvement [HR 2.55 (1.39–4.67); P = 0.002]; and of antiphospholipid syndrome (APS) [HR 4.92 (1.55–15.59); P = 0.007]. Conclusion Patients not achieving any kind of sustained remission have a higher risk of early mortality. White ethnicity, older age at diagnosis, absence of renal involvement and of APS were significantly associated with CR. Predictors for sustained CR do not change whether a 3-year or 5-year period is applied. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination. A case report.
- Author
-
Molina-Rios, Sebastian, Rojas-Martinez, Rigoberto, Estévez-Ramirez, Gloria Marcela, and Medina, Yimy Francisco
- Subjects
ANTIPHOSPHOLIPID syndrome ,SYSTEMIC lupus erythematosus ,SARS-CoV-2 ,COVID-19 vaccines - Published
- 2023
- Full Text
- View/download PDF
12. Autoimmune disease and COVID-19: a multicentre observational study in the United Kingdom.
- Author
-
Arachchillage, Deepa J, Rajakaruna, Indika, Pericleous, Charis, Nicolson, Philip L R, Makris, Mike, Laffan, Mike, and Group, the CA-COVID-19 Study
- Subjects
CLINICAL pathology ,RESEARCH ,COVID-19 ,SCIENTIFIC observation ,ANTIPHOSPHOLIPID syndrome ,MORTALITY ,AUTOIMMUNE diseases ,TREATMENT effectiveness ,COMPARATIVE studies ,RHEUMATOID arthritis ,ANEMIA ,LACTATE dehydrogenase ,DEMOGRAPHY ,SYSTEMIC lupus erythematosus ,CREATININE - Abstract
Objective To establish the demographic characteristics, laboratory findings and clinical outcomes in patients with autoimmune disease (AD) compared with a propensity-matched cohort of patients without AD admitted with COVID-19 to hospitals in the UK. Methods This is a multicentre observational study across 26 NHS Trusts. Data were collected both retrospectively and prospectively using a predesigned standardized case record form. Adult patients (≥18 years) admitted between 1 April 2020 and 31 July 2020 were included. Results Overall, 6288 patients were included to the study. Of these, 394 patients had AD prior to admission with COVID-19. Of 394 patients, 80 patients with SLE, RA or aPL syndrome were classified as severe rheumatologic AD. A higher proportion of those with AD had anaemia [240 (60.91%) vs 206 (52.28%), P = 0.015], elevated LDH [150 (38.08%) vs 43 (10.92%), P < 0.001] and raised creatinine [122 (30.96%) vs 86 (21.83%), P = 0.01], respectively. A significantly higher proportion of patients with severe rheumatologic AD had elevated CRP [77 (96.25%) vs 70 (87.5%), P = 0.044] and LDH [20 (25%) vs 6 (7.5%), P = 0.021]. Patients with severe rheumatologic AD had significantly higher mortality [32/80 (40%)] compared with propensity matched cohort of patients without AD [20/80 (25%), P = 0.043]. However, there was no difference in 180-day mortality between propensity-matched cohorts of patients with or without AD in general (P = 0.47). Conclusions Patients with severe rheumatologic AD had significantly higher mortality. Anaemia, renal impairment and elevated LDH were more frequent in patients with any AD while elevated CRP and LDH were more frequent in patients with severe rheumatologic AD both of which have been shown to associate with increased mortality in patients with COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey.
- Author
-
Pengo, Vittorio, Ross, Teresa Del, Tonello, Marta, Andreoli, Laura, Tincani, Angela, Gresele, Paolo, Silvestri, Elena, Simioni, Paolo, Campello, Elena, Hoxha, Ariela, Falanga, Anna, Ghirarduzzi, Angelo, Denas, Gentian, and collaborators, COVID-19 APS
- Subjects
THROMBOSIS ,COVID-19 ,ANTIPHOSPHOLIPID syndrome ,COVID-19 vaccines ,SURVEYS ,QUESTIONNAIRES ,MEDICAL referrals ,DRUG side effects ,DISEASE risk factors ,SYMPTOMS - Abstract
Objectives Patients with APS and triple-positive for aPL are at high risk of recurrent events. As COVID-19 and COVID-19 vaccination may induce thrombotic complications, the objective of the study was to assess the course of COVID-19 and adverse events after vaccination in these patients. Methods This is a nationwide multicentre survey conducted in nine APS referral centres by means of a questionnaire. Included patients are thrombotic APS with triple-positive aPL confirmed 12 weeks apart. Reference specialist physicians used a four-graded scale of severity for COVID-19 [from 0 (asymptomatic) to 3 (hospitalization in intensive care unit)] and a six-graded scale for adverse reactions to vaccination [from 0 (transient local injection site sign/symptoms) to 5 (potentially life-threatening reactions)]. Outcomes were considered within a 30-day period. Results Out of 161 patients interviewed, 18 (11%) had COVID-19. All of them fully recovered without any progression to severe disease nor thromboembolic event. A total of 146 patients received the first (92%) and 129 (80%) the second dose of vaccine; side effects were minimal and, in most cases (83% after the first and 68% after the second vaccination) limited to a sore arm. Fifteen patients (9%) were unvaccinated. Most of them raised doubts on the need for vaccination, complained of poor safety and in general were reluctant about COVID-19 vaccination. Conclusion Patients with triple-positive thrombotic APS did not suffer from severe COVID-19 outcomes. Importantly, COVID-19 vaccination was well tolerated. These data may reassure patients and physicians and contribute to reducing hesitancy in unvaccinated patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Antiphospholipid Antibodies and the Antiphospholipid Syndrome: From Coagulation to the Clinic.
- Author
-
Selby, Rita and Abdulrehman, Jameel
- Subjects
PHOSPHOLIPID antibodies ,ANTIPHOSPHOLIPID syndrome ,BLOOD coagulation - Published
- 2022
- Full Text
- View/download PDF
15. Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review.
- Author
-
Donnellan, Claire, Cohen, Hannah, and Werring, David J
- Subjects
COGNITION disorders ,BIOMARKERS ,ONLINE information services ,PSYCHOLOGY information storage & retrieval systems ,ANTIPHOSPHOLIPID syndrome ,SYSTEMATIC reviews ,MAGNETIC resonance imaging ,WHITE matter (Nerve tissue) ,DISEASE prevalence ,MEDLINE ,NEURORADIOLOGY ,CEREBRAL cortex - Abstract
Objectives Cognitive dysfunction is common in patients with aPL (including primary APS or APS associated with SLE). Neuroimaging biomarkers may contribute to our understanding of mechanisms of cognitive dysfunction in these cohorts. This review aimed to investigate: (i) the prevalence of cognitive dysfunction in studies including neuroimaging biomarkers; and (ii) associations between cognition and neuroimaging biomarkers in patients with APS/aPL. Methods We conducted a systematic search of electronic databases PubMed, Science Direct, Scopus and PsycINFO, and included studies with descriptions of neuroimaging findings, cognitive dysfunction or both, in patients with aPL positivity (LA, IgG and IgM aCL and anti-β2 glycoprotein-I antibodies). Results Of 120 search results we included 20 eligible studies (6 APS, 4 SLE with APS/aPL and 10 NPSLE). We identified a medium risk of bias in 6/11 (54%) of cohort studies and 44% of case–control studies, as well as marked heterogeneity in cognitive assessment batteries, APS and aPL definitions, and neuroimaging modalities and protocols. The prevalence of cognitive dysfunction ranged between 11 and 60.5%. Structural MRI was the most common imaging modality, reporting cognitive dysfunction to be associated with white matter hyperintensities, ischaemic lesions and cortical atrophy (four with cerebral atrophy, two with white matter hyperintensities and two with cerebral infarcts). Conclusion Our findings confirm that cognitive impairment is commonly found in patients with aPL (including APS, SLE and NPSLE). The risk of bias, and heterogeneity in the cognitive and neuroimaging biomarkers reported does not allow for definitive conclusions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century—an observational study from the Lupus-Cruces cohort.
- Author
-
Ugarte, Amaia, Bustos, Alazne Garcia de, Ruiz-Arruza, Ioana, Soto-Peleteiro, Adriana, Martin-Iglesias, Daniel, Gonzalez-Echavarri, Cristina, and Ruiz-Irastorza, Guillermo
- Subjects
SYSTEMIC lupus erythematosus diagnosis ,AUTOANTIBODIES ,CARDIOVASCULAR diseases risk factors ,PATIENT aftercare ,CONFIDENCE intervals ,ANTIPHOSPHOLIPID syndrome ,COMPARATIVE studies ,VITAMIN D ,DESCRIPTIVE statistics ,ASPIRIN ,PREDICTION models ,PREDNISONE ,IMMUNOSUPPRESSIVE agents ,ODDS ratio ,HYDROXYCHLOROQUINE ,LONGITUDINAL method - Abstract
Objective To compare the influence of aPLs on global and cardiovascular damage in patients with SLE diagnosed before and after the year 2000. Methods Two hundred and eighty-six patients from the Lupus-Cruces cohort with a minimum follow-up of 5 years were divided into two subcohorts according to the date of diagnosis, before 2000 (less than 2000) and from 2000 on (2000 or more). We compared the mean Systemic Lupus Erythematosus International Collaborating Clinics-American College of Rheumatology (SLICC-ACR) Damage Index score and global and cardiovascular damage-free survival rates in the presence or absence of aPL in both subcohorts. Variables potentially modulating damage among aPL-positive patients were analysed. Results The subcohorts were comparable for demographic and lupus-related variables except for treatment variables: the 2000 or more subcohort received lower doses of prednisone and more HCQ, low-dose aspirin, statins, immunosuppressive agents and vitamin D. aPL-positive patients in the less than 2000, but not in the 2000 or more subcohort, accrued more damage compared with aPL-negative patients. In the less than 2000 subcohort, the adjusted hazard ratios (HRs) for global and cardiovascular damage in aPL-positive vs aPL-negative patients were 1.98 (95% CI 1.24, 3.14) and 9.3 (95% CI 3.24, 26.92), respectively. No differences in damage were seen between aPL-positive and aPL-negative patients in the 2000 or more subcohort. Hypertension (HR = 4.64, 95% CI 1.33, 16.19), LA (HR = 3.85, 95% CI 1.1, 13.41) and the number of months on HCQ (HR = 0.97, 95% CI 0.95, 0.99) were independent predictors of vascular damage in the combined analysis of all aPL-positive patients. Conclusion The effects of aPL on damage accrual in SLE patients have been reduced over recent years. The widespread use of HCQ and a better thromboprophylaxis are likely causing this change. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies.
- Author
-
Ali, Omar Hasan, Bomze, David, Risch, Lorenz, Brugger, Silvio D, Paprotny, Matthias, Weber, Myriam, Thiel, Sarah, Kern, Lukas, Albrich, Werner C, Kohler, Philipp, Kahlert, Christian R, Vernazza, Pietro, Bühler, Philipp K, Schüpbach, Reto A, Gómez-Mejia, Alejandro, Popa, Alexandra M, Bergthaler, Andreas, Penninger, Josef M, and Flatz, Lukas
- Subjects
AUTOANTIBODIES ,DIAGNOSTIC reagents & test kits ,RESPIRATORY mucosa ,COVID-19 ,IMMUNOGLOBULINS ,ANTIPHOSPHOLIPID syndrome ,RETROSPECTIVE studies ,TERTIARY care ,COMPARATIVE studies ,SEVERITY of illness index ,MEDICAL records ,DESCRIPTIVE statistics ,STATISTICAL correlation ,VIRAL antibodies ,DATA analysis software ,LONGITUDINAL method - Abstract
Background Severe coronavirus disease 2019 (COVID-19) frequently entails complications that bear similarities to autoimmune diseases. To date, there are little data on possible immunoglobulin (Ig) A–mediated autoimmune responses. Here, we aim to determine whether COVID-19 is associated with a vigorous total IgA response and whether IgA antibodies are associated with complications of severe illness. Since thrombotic events are frequent in severe COVID-19 and resemble hypercoagulation of antiphospholipid syndrome, our approach focused on antiphospholipid antibodies (aPL). Methods In this retrospective cohort study, clinical data and aPL from 64 patients with COVID-19 were compared from 3 independent tertiary hospitals (1 in Liechtenstein, 2 in Switzerland). Samples were collected from 9 April to 1 May 2020. Results Clinical records of 64 patients with COVID-19 were reviewed and divided into a cohort with mild illness (mCOVID; 41%), a discovery cohort with severe illness (sdCOVID; 22%) and a confirmation cohort with severe illness (scCOVID; 38%). Total IgA, IgG, and aPL were measured with clinical diagnostic kits. Severe illness was significantly associated with increased total IgA (sdCOVID, P =.01; scCOVID, P <.001), but not total IgG. Among aPL, both cohorts with severe illness significantly correlated with elevated anticardiolipin IgA (sdCOVID and scCOVID, P <.001), anticardiolipin IgM (sdCOVID, P =.003; scCOVID, P <.001), and anti–beta 2 glycoprotein-1 IgA (sdCOVID and scCOVID, P <.001). Systemic lupus erythematosus was excluded from all patients as a potential confounder. Conclusions Higher total IgA and IgA-aPL were consistently associated with severe illness. These novel data strongly suggest that a vigorous antiviral IgA response, possibly triggered in the bronchial mucosa, induces systemic autoimmunity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Indication and outcome of lupus anticoagulant and antiphospholipid antibodies testing in routine clinical practice.
- Author
-
Kempers, Eva K, Dalm, Virgil A S H, Rijn, Marie Josee E van, Mulders, Annemarie G M G J, Leebeek, Frank W G, Maat, Moniek P M de, and Jansen, A J Gerard
- Subjects
BLOOD coagulation disorders ,ANTIPHOSPHOLIPID syndrome ,AUTOIMMUNE disease diagnosis - Abstract
Objectives Lupus anticoagulans (LACs) and aPLs, both further summarized as aPL, are frequently assessed in routine daily clinical practice in diagnostic workups for suspected autoimmune diseases or to test for underlying risk factors in patients with thrombosis or obstetric complications. The aim of this study was to determine the prevalence of aPL positivity in patients with an indication for aPL testing in routine clinical practice. Methods In this retrospective single-centre study, indication for aPL testing, aPL test results and clinical data were collected for patients tested between June 2015 and April 2018. Results During the study period, 16 847 single aPL tests were performed in 2139 patients. In 212 patients one or more positive aPL test was found, confirmed in 43.9% with a second positive test. Indications for aPL testing were diagnostic workup/follow-up of autoimmune diseases (33.6%), thrombosis (21.4%) and obstetric complications (28%). Seventy-four patients (3.5% of all patients) fulfilled the criteria of APS, of whom 51% were newly diagnosed. Second positive aPL titres and titres of APS patients were significantly higher compared with positive aPL titres at the first measurement (P < 0.05). Patients with indications of arterial thrombosis and diagnostic workup/follow-up of autoimmune diseases had significantly higher levels of aCL IgG and anti-β2 glycoprotein I (β2GPI) IgG compared with patients with other indications. Conclusion The prevalence of one or more positive aPL test was 9.9% and APS was diagnosed in 3.5% of the patients. Patients with arterial thrombosis had significantly higher anti-β2GPI IgG and aCL IgG, which should be confirmed in future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Anti‐vimentin/cardiolipin IgA in the anti‐phospholipid syndrome: A new tool for 'seronegative' diagnosis.
- Author
-
Capozzi, Antonella, Riitano, Gloria, Mancuso, Silvia, Recalchi, Serena, Manganelli, Valeria, Garofalo, Tina, Alessandri, Cristiano, Longo, Agostina, Misasi, Roberta, Conti, Fabrizio, Truglia, Simona, and Sorice, Maurizio
- Subjects
ANTIPHOSPHOLIPID syndrome ,IMMUNOGLOBULIN A ,DIAGNOSIS ,PHOSPHOLIPID antibodies ,ENZYME-linked immunosorbent assay ,SYMPTOMS - Abstract
Anti‐phospholipid syndrome (APS) is a systemic autoimmune disorder defined by the simultaneous presence of vascular clinical events, pregnancy morbidity and anti‐phospholipid antibodies (aPL). In clinical practice, it is possible to find patients with APS who are persistently negative for the routine aPL tests (seronegative APS; SN‐APS). Recently, the identification of aPL immunoglobulin (Ig)A and/or anti‐β2‐glycoprotein‐I (β2‐GPI) IgA was shown to represent a further test in SN‐APS patients. In this study we analyzed the presence of anti‐vimentin/cardiolipin (aVim/CL) IgA in a large cohort of patients with SN‐APS, evaluating their possible association with clinical manifestations of the syndrome. This study includes 60 consecutive SN‐APS patients, 30 patients with APS and 40 healthy donors. aVim/CL IgA were detected by enzyme‐linked immunosorbent assay (ELISA). Results show that 12 of 30 APS patients (40%) and 16 of 60 SN‐APS patients (26.7%) resulted positive for aVim/CL IgA. Interestingly, SN‐APS patients who tested positive for aVim/CL IgA showed a higher prevalence of arterial thrombosis (p = 0.017, likelihood positive ratio = 5.7). This study demonstrates for the first time, to our knowledge, the presence of aVim/CL IgA in sera of patients with APS. In particular, they revealed a potential usefulness in identification of a significant proportion of SN‐APS patients. Moreover, as patients tested positive for aVim/CL IgA reported a high likelihood ratio to have the clinical features of APS, this test may be considered a suitable approach in the clinical evaluation of SN‐APS. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. pivotal role of endothelial protein C receptor for antiphospholipid antibody-mediated pathologies.
- Author
-
Chu, Cong-Qiu
- Subjects
AUTOANTIBODIES ,ENDOTHELIAL cells ,BLOOD proteins ,ANTIPHOSPHOLIPID syndrome ,CELL receptors ,GLYCOPROTEINS ,VASCULAR endothelial growth factors ,TOLL-like receptors - Abstract
The author explains the role of endothelial protein C receptor for antiphospholipid antibody-mediated pathologies. Topics he covered include the clinical presentation of patients with antiphospholipid syndrome (APS), the similarities between endothelial protein C receptor (EPCR) and CD1 family of proteins and the expression of EPCR by a variety of cell types.
- Published
- 2022
- Full Text
- View/download PDF
21. Anti–Domain I β2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.
- Subjects
GLYCOPROTEINS ,ACTIVATED protein C resistance ,ANTIPHOSPHOLIPID syndrome ,SYSTEMIC lupus erythematosus ,ENZYME-linked immunosorbent assay - Abstract
Background: Antibodies binding to domain I of β
2 -glycoprotein I (aDI) and activated protein C (APC) resistance are associated with an increased risk of thrombosis in cross-sectional studies. The objective of this study was to assess their predictive value for future thromboembolic events in patients with antiphospholipid antibodies (aPL) or antiphospholipid syndrome. Methods: This prospective multicenter cohort study included consecutive patients with aPL or systemic lupus erythematosus. We followed 137 patients (43.5 ± 15.4 year old; 107 women) for a mean duration of 43.1 ± 20.7 months. Results: We detected aDI IgG antibodies by ELISA in 21 patients. An APC sensitivity ratio (APCsr) was determined using a thrombin generation–based test. The APCsr was higher in patients with anti–domain I antibodies demonstrating APC resistance (0.75 ± 0.13 vs 0.48 ± 0.20, P < 0.0001). In univariate analysis, the hazard ratio (HR) for thrombosis over time was higher in patients with aDI IgG (3.31 [95% CI, 1.15–9.52]; P = 0.03) and patients with higher APC resistance (APCsr >95th percentile; HR, 6.07 [95% CI, 1.69–21.87]; P = 0.006). A sensitivity analysis showed an increased risk of higher aDI IgG levels up to HR 5.61 (95% CI, 1.93–16.31; P = 0.01). In multivariate analysis, aDI IgG (HR, 3.90 [95% CI, 1.33–11.46]; P = 0.01) and APC resistance (HR, 4.98 [95% CI, 1.36–18.28]; P = 0.02) remained significant predictors of thrombosis over time. Conclusions: Our study shows that novel tests for antibodies recognizing domain I of β2 -glycoprotein I and functional tests identifying APC resistance are significant predictors of thrombosis over time and may be useful for risk stratification. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
22. Diagnosis and treatment of patients with antiphospholipid syndrome: a mixed-method evaluation of care in The Netherlands.
- Author
-
Haneveld, Mirthe J Klein, Lemmen, Caro H C, Brunekreef, Tammo E, Bijl, Marc, Jansen, A J Gerard, Leeuw, Karina de, Spierings, Julia, Limper, Maarten, and Group, ARCH Study
- Subjects
ANTIPHOSPHOLIPID syndrome treatment ,MEDICAL specialties & specialists - Abstract
Objectives The aims were to gain insight into the care provided to patients with APS in The Netherlands and to identify areas for improvement from the perspective of both patients and medical specialists. Methods APS care was evaluated using qualitative and quantitative methods. Perspectives on APS care were explored using semi-structured interviews with medical specialists, patient focus groups and a cross-sectional, online patient survey. In order to assess current practice, medical records were reviewed retrospectively to collect data on clinical and laboratory manifestations and pharmacological treatment in six Dutch hospitals. Results Fourteen medical specialists were interviewed, 14 patients participated in the focus groups and 79 patients completed the survey. Medical records of 237 patients were reviewed. Medical record review showed that only one-third of patients were diagnosed with APS within 3 months after entering specialist care. The diagnostic approach and management varied between centres and specialists. Almost 10% of all patients and 7% of triple-positive patients with thrombotic APS were not receiving any anticoagulant treatment at the time of medical record review. Correspondingly, poor recognition and fragmentation of care were reported as the main problems by medical specialists. Additionally, patients reported the lack of accessible, reliable patient education, psychosocial support and trust in physicians as important points for improvement. Conclusion Delayed diagnosis, variability in management strategies and fragmentation of care were important limitations of APS care identified in this study. A remarkable 10% of patients did not receive any anticoagulant treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. CLINICAL NEPHROLOGY.
- Subjects
ANTIPHOSPHOLIPID syndrome ,INTERSTITIAL nephritis ,PATIENTS' attitudes ,KARNOFSKY Performance Status ,CHRONIC kidney failure ,BODY mass index ,HANSEN'S disease - Published
- 2020
- Full Text
- View/download PDF
24. Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry.
- Author
-
Alijotas-Reig, Jaume, Esteve-Valverde, Enrique, Ferrer-Oliveras, Raquel, Sáez-Comet, Luis, Lefkou, Elmina, Mekinian, Arsène, Belizna, Cristina, Ruffatti, Amelia, Hoxha, Ariela, Tincani, Angela, Nalli, Cecilia, Marozio, Luca, Maina, Aldo, Espinosa, Gerard, Ríos-Garcés, Roberto, Cervera, Ricard, Carolis, Sara De, Monteleone, Giuseppina, Latino, Omar, and Udry, Sebastian
- Subjects
ANTIPHOSPHOLIPID syndrome ,CHILDBIRTH ,COMPARATIVE studies ,CLINICAL pathology ,LONGITUDINAL method ,OBSTETRICS ,PATHOLOGICAL laboratories ,THROMBOSIS ,TREATMENT effectiveness ,RETROSPECTIVE studies ,DESCRIPTIVE statistics - Abstract
Objectives To compare clinical features, laboratory data and fetal-maternal outcomes between 1000 women with obstetric APS (OAPS) and 640 with aPL-related obstetric complications not fulfilling Sydney criteria (non-criteria OAPS, NC-OAPS). Methods This was a retrospective and prospective multicentre study from the European Registry on Obstetric Antiphospholipid Syndrome. Results A total of 1650 women with 5251 episodes, 3601 of which were historical and 1650 latest episodes, were included. Altogether, 1000 cases (OAPS group) fulfilled the Sydney classification criteria and 650 (NC-OAPS group) did not. Ten NC-OAPS cases were excluded for presenting thrombosis during follow-up. All cases were classified as category I (triple positivity or double positivity for aPL) or category II (simple positivity). Overall, aPL laboratory categories showed significant differences: 29.20% in OAPS vs 17.96% in NC-OAPS (P < 0.0001) for category I, and 70.8% in OAPS vs 82% in NC-OAPS (P < 0.0001) for category II. Significant differences were observed when current obstetric complications were compared (P < 0.001). However, major differences between groups were not observed in treatment rates, livebirths and thrombotic complications. In the NC-OAPS group, 176/640 (27.5%) did not fulfil Sydney clinical criteria (subgroup A), 175/640 (27.34%) had a low titre and/or non-persistent aPL positivity but did meet the clinical criteria (subgroup B) and 289/640 (45.15%) had a high aPL titre but did not fulfil Sydney clinical criteria (subgroup C). Conclusion Significant clinical and laboratory differences were found between groups. Fetal-maternal outcomes were similar in both groups when treated. These results suggest that we could improve our clinical practice with better understanding of NC-OAPS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. Recurrent pregnancy loss: diagnostic workup after two or three pregnancy losses? A systematic review of the literature and meta-analysis.
- Author
-
Dijk, Myrthe M van, Kolte, Astrid M, Limpens, Jacqueline, Kirk, Emma, Quenby, Siobhan, Wely, Madelon van, Goddijn, Mariëtte, van Dijk, Myrthe M, and van Wely, Madelon
- Subjects
RECURRENT miscarriage ,ANTIPHOSPHOLIPID syndrome ,META-analysis ,PREGNANCY ,PROGNOSTIC tests - Abstract
Background: Recurrent pregnancy loss (RPL) occurs in 1-3% of all couples trying to conceive. No consensus exists regarding when to perform testing for risk factors in couples with RPL. Some guidelines recommend testing if a patient has had two pregnancy losses whereas others advise to test after three losses.Objective and Rationale: The aim of this systematic review was to evaluate the current evidence on the prevalence of abnormal test results for RPL amongst patients with two versus three or more pregnancy losses. We also aimed to contribute to the debate regarding whether the investigations for RPL should take place after two or three or more pregnancy losses.Search Methods: Relevant studies were identified by a systematic search in OVID Medline and EMBASE from inception to March 2019. A search for RPL was combined with a broad search for terms indicative of number of pregnancy losses, screening/testing for pregnancy loss or the prevalence of known risk factors. Meta-analyses were performed in case of adequate clinical and statistical homogeneity. The quality of the studies was assessed using the Newcastle-Ottawa scale.Outcomes: From a total of 1985 identified publications, 21 were included in this systematic review and 19 were suitable for meta-analyses. For uterine abnormalities (seven studies, odds ratio (OR) 1.00, 95% CI 0.79-1.27, I2 = 0%) and for antiphospholipid syndrome (three studies, OR 1.04, 95% CI 0.86-1.25, I2 = 0%) we found low quality evidence for a lack of a difference in prevalence of abnormal test results between couples with two versus three or more pregnancy losses. We found insufficient evidence of a difference in prevalence of abnormal test results between couples with two versus three or more pregnancy losses for chromosomal abnormalities (10 studies, OR 0.78, 95% CI 0.55-1.10), inherited thrombophilia (five studies) and thyroid disorders (two studies, OR 0.52, 95% CI: 0.06-4.56).Wider Implications: A difference in prevalence in uterine abnormalities and antiphospholipid syndrome is unlikely in women with two versus three pregnancy losses. We cannot exclude a difference in prevalence of chromosomal abnormalities, inherited thrombophilia and thyroid disorders following testing after two versus three pregnancy losses. The results of this systematic review may support investigations after two pregnancy losses in couples with RPL, but it should be stressed that additional studies of the prognostic value of test results used in the RPL population are urgently needed. An evidenced-based treatment is not currently available in the majority of cases when abnormal test results are present. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
26. Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome.
- Author
-
Hiroyuki Yoshihara, Mayumi Sugiura-Ogasawara, Tamao Kitaori, Kinue Katano, and Yasuhiko Ozaki
- Subjects
CHILDBIRTH ,ANTIPHOSPHOLIPID syndrome ,PREGNANCY ,PERINATAL death ,ECTOPIC pregnancy - Abstract
Objectives: The objective is to evaluate whether danaparoid is effective in improving the live birth rate in patients with obstetric antiphospholipid syndrome (oAPS). Methods: This prospective study included 91 pregnancies of 60 patients with oAPS diagnosed according to criteria of the International Congress on APS. Live birth rates, adverse pregnancies and perinatal outcomes were compared among patients treated with danaparoid and low dose aspirin (danaparoid group, LDA), unfractionated heparin (UFH) and LDA (UFH group) and LDA and/or prednisolone (LDA group). Results: After excluding 11 miscarriages with abnormal embryonic chromosomes, one chemical pregnancy and one ectopic pregnancy, live birth rates were 87.5% (14/16) for the danaparoid group, 90.0% (36/40) for the UFH group and 63.6% (14/22) for the LDA group, respectively. The live birth rates of patients treated with danaparoid and UFH were similar and tended to be higher than that of patients treated with LDA, respectively (OR 4.0, 95% confidence interval 0.72-22.22 and 5.15, 1.33-20.00). No patient given danaparoid and one patient with UFH developed heparin-induced thrombocytopenia which resulted in a stillbirth. Another patient with UFH suffered a lumbar compression fracture. Conclusion: Danaparoid is effective for improving the live birth rate and is safe for patients with oAPS. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases.
- Author
-
Gulli, F., Napodano, C., Marino, M., Ciasca, G., Pocino, K., Basile, V., Visentini, M., Stefanile, A., Todi, L., De Spirito, M., Rapaccini, G. L., and Basile, U.
- Subjects
RHEUMATISM ,AUTOIMMUNE diseases ,SJOGREN'S syndrome ,SYSTEMIC lupus erythematosus ,ANTIPHOSPHOLIPID syndrome ,HEPATITIS C virus ,MONOCLONAL gammopathies ,IMMUNOGLOBULIN light chains - Abstract
Summary: Several reports have highlighted the abnormal increments of serum immunoglobulin free light chains (FLCs) in the course of systemic autoimmune rheumatic diseases (SARD), but a comparative analysis among different conditions is still lacking. A strong association between elevated FLC and hepatitis C virus (HCV)‐related mixed cryoglobulinaemia (HCVMC) has been well established. Here, we aimed to analyse serum FLC levels in patients with four different SARD in comparison with HCVMC. Using a turbidimetric assay, free κ and λ chains were quantified in sera from 198 SARD patients (37 rheumatoid arthritis, RA; 47 systemic lupus erythematosus, SLE; 52 anti‐phospholipid syndrome, APS; 62 primary Sjogren's syndrome, pSS), 62 HCVMC and 50 healthy blood donors (HD). All patient groups showed increased κ levels when compared to HD: 33·5 ± 2·6 mg/l in HCVMC, 26·7 ± 2·3 mg/l in RA, 29·7 ± 1·9 mg/l in SLE, 23·8 ± 1·1 mg/l in APS, 24·2 ± 1·1 mg/l in pSS; 10·1 ± 0·6 mg/l in HD. Free λ levels displayed a significant increase only for HCVMC (20·4 ± 1·4 mg/l) and SLE (18·4 ± 1·0 mg/l) compared to HD (13·6 ± 0·9 mg/l). The increase of κ compared to λ takes into account a κ /λ ratio of 1·6 for all groups. Our results substantially analyse and strengthen the association between FLC and SARD focusing the questions regarding their role in the pathogenesis and diagnosis of human diseases. Unfortunately, the biochemical differences distinguishing normal from pathological FLC have not been identified. Production of different isotypes is probably connected to still‐unknown pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?
- Author
-
Pericleous, Charis, D'Souza, Amrita, McDonnell, Thomas, Ripoll, Vera M, Leach, Oliver, Isenberg, David, Giles, Ian, and Rahman, Anisur
- Subjects
ANTICOAGULANTS ,ANTIPHOSPHOLIPID syndrome ,AUTOANTIBODIES ,BLOOD collection ,BLOOD vessels ,CARDIOVASCULAR agents ,CARDIOVASCULAR diseases ,COMPARATIVE studies ,ENZYME-linked immunosorbent assay ,GLYCOPROTEINS ,IMMUNOGLOBULINS ,MEDICAL records ,PHOSPHOLIPIDS ,SYSTEMIC lupus erythematosus ,THROMBOSIS ,DNA-binding proteins ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,ACQUISITION of data methodology ,CHEMICAL inhibitors - Abstract
Objectives aPL are present in between 20 and 30% of patients with SLE. They can cause vascular events (VE) or pregnancy morbidity. aCL and anti-beta-2-glycoprotein I (anti-β2GPI) are measured in clinical practice. Domain I (DI) of β2GPI is the main site for aPL binding. We investigated the prevalence of IgG anti-DI, aCL and anti-β2GPI antibodies in early SLE and their association with mortality and development of VE. Methods Samples from 501 patients with SLE that had been obtained and stored early during their disease were tested for IgG anti-DI, aCL and anti-β2GPI antibodies by ELISA. LA status and history of VE were obtained by reviewing medical records. Kaplan–Meier analysis was used to investigate mortality and occurrence of VE, comparing groups with and without aPL in early disease. Results Of 501 patients, 190 (38%) had at least one of these aPL, of whom 112 had anti-DI alone. Of 276 patients with complete vascular history, 83 had experienced VE. The 39 patients who were double or triple-ELISA-positive for any combination of the three aPL were more likely to have or develop lupus anticoagulant (P <0.0001) than those who were single-ELISA-positive or negative. In Kaplan–Meier analysis, they showed a trend towards developing more VE (P = 0.06). Conclusion IgG anti-DI antibodies were present in early serum samples from 29% of patients and were more common than IgG aCL or anti-β2GPI. There was some evidence suggesting that double or triple-ELISA-positivity for these antibodies identified a group with worse outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. Comment on: EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies.
- Author
-
Rosa, Gilberto Pires da, Bettencourt, Paulo, Ferreira, Ester, Reverter, Joan-Carles, Cervera, Ricard, and Espinosa, Gerard
- Subjects
BIOMARKERS ,ENOXAPARIN ,ANTIPHOSPHOLIPID syndrome ,PREGNANCY complications ,ASPIRIN ,PREDICTION models ,ALGORITHMS ,WOMEN'S health ,DISEASE risk factors ,DISEASE complications ,PREGNANCY - Published
- 2021
- Full Text
- View/download PDF
30. Comment on: EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies: reply.
- Author
-
Chighizola, Cecilia Beatrice and Pregnolato, Francesca
- Subjects
AUTOANTIBODIES ,ANTIPHOSPHOLIPID syndrome ,PREGNANCY complications ,PREDICTION models ,ALGORITHMS ,DISEASE risk factors - Published
- 2021
- Full Text
- View/download PDF
31. Kidney disease in primary anti-phospholipid antibody syndrome.
- Author
-
Gracia-Tello, Borja and Isenberg, David
- Subjects
ANTIPHOSPHOLIPID syndrome ,KIDNEY diseases ,THROMBOSIS ,SYSTEMATIC reviews ,SEARCH engines - Abstract
APS is an autoimmune disease defined by the presence of arterial or venous thrombotic events and/or pregnancy morbidity in patients who test positive for aPL. APS can be isolated (primary APS) or associated with other autoimmune diseases. The kidney is a major target organ in APS, and renal thrombosis can occur at any level within the vasculature of the kidney (renal arteries, intrarenal vasculature and renal veins). Histological findings vary widely, including ischaemic glomeruli and thrombotic lesions without glomerular or arterial immune deposits on immunofluorescence. Renal involvement in patients with definite APS is treated with long-term anticoagulants as warfarin, but new treatments are being tried. The aim of this article is to review the links between primary APS and kidney disease. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
32. Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches.
- Author
-
López-Pedrera, Chary, Barbarroja, Nuria, Jimenez-Gomez, Yolanda, Collantes-Estevez, Eduardo, Angeles Aguirre, Maria, and Jose Cuadrado, Maria
- Subjects
ANTICOAGULANTS ,THERAPEUTIC use of antioxidants ,STATINS (Cardiovascular agents) ,REACTIVE oxygen species ,ANTIPHOSPHOLIPID syndrome ,ATHEROSCLEROSIS ,AUTOANTIBODIES ,BLOOD proteins ,CARDIOVASCULAR diseases ,SYSTEMIC lupus erythematosus ,THROMBOSIS ,OXIDATIVE stress ,DISEASE complications - Abstract
Atherothrombosis is a recurrent complication in APS and SLE patients. Oxidative stress has been suggested as a key player underlying this process. Autoantibodies have been pointed to as the main contributors to abnormality in the oxidative status observed in APS and SLE patients, promoting the increased production of oxidant species and the reduction of antioxidant molecules. This imbalance causes vascular damage through the activation of immune cells, including monocytes, lymphocytes and neutrophils, causing the expression of pro-inflammatory and procoagulant molecules, the formation of neutrophil extracellular traps and the adhesion of these cells to the endothelium; the induction of cellular apoptosis and impaired cell clearance, which in turn enhances autoantibody neogeneration; and cytotoxicity of endothelial cells. This review describes the mechanisms underlying the role of oxidative stress in the pathogenesis of atherothrombosis associated with APS and SLE, focused on the effect of autoantibodies, the different cell types involved and the diverse effectors, including cytokines, procoagulant proteins and their main modulators, such as oxidant/antioxidant species and intracellular pathways in each pathology. We further discuss new therapies aimed at restoring the oxidative stress balance and subsequently to tackle atherothrombosis in APS and SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Ribophorin II is involved in the tissue factor expression mediated by phosphatidylserine-dependent antiprothrombin antibody on monocytes.
- Author
-
Yuichiro Fujieda, Olga Amengual, Masaki Matsumoto, Kimiko Kuroki, Hidehisa Takahashi, Michihito Kono, Takashi Kurita, Kotaro Otomo, Masaru Kato, Kenji Oku, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda, Katsumi Maenaka, Shigetsugu Hatakeyama, Keiichi I. Nakayama, and Tatsuya Atsumi
- Subjects
ANTIPHOSPHOLIPID syndrome ,CELL culture ,CHI-squared test ,ENZYME-linked immunosorbent assay ,FISHER exact test ,FLOW cytometry ,GENE expression ,IMMUNOGLOBULINS ,LIQUID chromatography ,MASS spectrometry ,MEMBRANE proteins ,MONOCLONAL antibodies ,POLYMERASE chain reaction ,RESEARCH funding ,RNA ,THROMBOSIS ,PROTEOMICS ,DATA analysis software ,DESCRIPTIVE statistics ,PROTHROMBIN time ,IN vitro studies ,DISEASE complications - Abstract
Objective. Phosphatidylserine-dependent, also called aPS-PT, recognizes the phosphati dylserine-prothrombin complex, which is associated with APS. We have previously reported that aPS-PT induces tissue factor (TF) expression on monocytes through the p38 mitogen-activated protein kinase pathway. However, the cell surface interaction between prothrombin and aPS-PT, which is involved in the activation of cell-signalling pathways, has remained unknown. The objective of this study was to identify membrane proteins involved in the binding of prothrombin and aPS-PT to monocyte surfaces as well as the induction of TF expression. Methods. RAW264.7 cells with FLAG-tagged prothrombin were incubated and separated using affinity chromatography with anti-FLAG antibody-conjugated Sepharose beads. Immunopurified proteins were then analysed by an online nano-liquid chromatography-tandem mass spectrometry. The binding between prothrombin and the identified protein, ribophorin II (RPN2), was analysed by ELISA and surface plasmon resonance. To elucidate the role of RPN2 in TF expression, the TF mRNA level in RAW264.7 cells treated with RPN2 small interfering RNA was determined by quantitative real-time PCR (qPCR). Results. RPN2 was identified as a candidate molecule involved in the binding of prothrombin to the cell surface. The binding between prothrombin and RPN2 was confirmed by ELISA and surface plasmon resonance. RAW264.7 cells treated with RPN2 small interfering RNA showed significant reduction of the TF expression mediated by prothrombin and a mouse monoclonal aPS-PT. Conclusion. We identified that RPN2 is one of the prothrombin-binding proteins on monocyte surfaces, suggesting that RPN2 is involved in the pathophysiology of thrombosis in patients with APS. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
34. Higher levels of procoagulant microparticles in women with recurrent miscarriage are not associated with antiphospholipid antibodies.
- Author
-
Martínez-Zamora, M. A., Tàssies, D., Creus, M., Reverter, J. C., Puerto, B., Monteagudo, J., Carmona, F., and Balasch, J.
- Subjects
RECURRENT miscarriage ,PHOSPHOLIPID antibodies ,BLOOD coagulation ,ANTIPHOSPHOLIPID syndrome ,FIRST trimester of pregnancy ,PATIENTS ,DIAGNOSIS ,AUTOANTIBODIES ,CELL membranes ,CASE-control method ,DISEASE complications - Abstract
Study Question: Are the levels of circulating cell-derived microparticles (cMPs) in patients with recurrent miscarriage (RM) associated with the antiphospholipid syndrome (APS)?Summary Answer: cMPs in women with RM are not associated with antiphospholipid antibodies (aPLs).What Is Known Already: Previous studies have focused on cMP levels in RM patients. Most studies have shown higher levels of cMPs in RM patients whereas others have reported lower levels. Data regarding cMPs in patients with the APS are scanty in the literature.Study Design, Size, Duration: A case-control study including three groups of patients. A total of 154 women were prospectively recruited from September 2009 to October 2013. Four patients refused to participate. The APS group consisted of 50 women that had been previously diagnosed with primary APS and had had ≥3 consecutive first trimester miscarriages. The uRM group included 52 couples with ≥3 consecutive first trimester miscarriages of unknown etiology. The fertile control (FER) group was composed of 52 healthy fertile women with no history of pregnancy losses. Miscarriage was defined as intrauterine pregnancy loss at <10 weeks' size on ultrasound.Participants/materials, Setting, Methods: Venous blood samples for coagulation studies and cMP determinations were obtained. All patients underwent a thrombophilia study.Main Results and the Role Of Chance: cMP levels were significantly higher in the APS and uRM groups versus the FER group (P < 0.0001 and P = 0.009, respectively) (cMP number × 10(3)/ml plasma [mean ± SD]: APS: 18.5 ± 13.6; uRM: 16.3 ± 13.8; FER: 9.7 ± 4.6). There were no statistically significant differences in cMP levels between the APS and uRM groups.Limitations, Reasons For Caution: The sample size was arbitrarily decided according to previous studies analyzing cMPs in RM patients. Different cMP subtypes were not investigated.Wider Implications Of the Findings: The present study adds further data on the subject showing that patients with RM, irrespective of testing positive for aPLs, have increased levels of cMPs compared with healthy fertile controls. The presence of elevated cMPs in RM women may reflect an ongoing systemic pathological, albeit asymptomatic, status that can become deleterious in the setting of pregnancy.Study Funding/competing Interests: This study was supported in part by grant from FIS-PI11/01560 within the 'Plan Nacional de I+D+I' and co-funded by the 'ISCIII-Subdirección General de Evaluación' and the 'Fondo Europeo de Desarrollo Regional (FEDER)'. The authors have no competing interests to disclose.Trial Registration Number: Not applicable. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
35. Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review.
- Author
-
Rodríguez-García, Veronica, Ioannou, Yiannis, Fernández-Nebro, Antonio, Isenberg, David A., and Giles, Ian P.
- Subjects
ANTIPHOSPHOLIPID syndrome ,CHI-squared test ,ENZYME-linked immunosorbent assay ,IMMUNOGLOBULINS ,MEDICAL information storage & retrieval systems ,MEDLINE ,META-analysis ,ONLINE information services ,RESEARCH funding ,SYSTEMATIC reviews ,DIAGNOSIS - Abstract
Objective. To systematically review and establish the prevalence of antibody positivity in assays not currently included in the APS classification criteria to detect antibodies directed against other phospho-lipids (PLs), PL binding proteins, coagulation factors and a mechanistic test for resistance of Annexin A5 (AnxA5) anticoagulant activity in APS and control populations. Methods. We searched PubMed and EMBASE using the key words APS, antiphospholipid antibodies, non-criteria, new assays, IgA anticardiolipin antibodies, lupus anticoagulant, anti-Domain I, IgA anti-b2-glycoprotein I antibodies, antiphosphatidylserine, anti-phosphatidylethanolamine, anti-phosphatidic acid, antiprothrombin, antiphosphatidylserine-prothtombin, anti-vimentin/cardiolipin complex and Annexin A5 resistance. Studies that met inclusion criteria to describe prevalence of non-criteria aPLs in APS patients (n>10), disease and healthy control subjects were systematically examined. Results. We selected 16 retrospective studies of 1404 APS patients, 1839 disease control and 797 healthy controls. The highest prevalence of non-criteria aPLs in the largest number of patients with APS was found in IgA anti-β2GPI studies (129/229, 56.3%), AnxA5R (87/163, 53.4%) and IgG anti-Domain I (241/548, 44.0%). Conclusion. Our finding of a significantly high prevalence of all non-criteria aPLs studied in patients with APS compared with controls was tempered by wide variation in sample size, retrospective collection, assay methodology and different determination of positivity. Therefore, prospective studies of sufficient size and appropriate methodology are required to evaluate the significance of these assays and their utility in the management of patients with APS. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
36. Comment on: Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis. Reply.
- Author
-
Bettiol, Alessandra, Mattioli, Irene, Emmi, Giacomo, Minno, Matteo Nicola Dario Di, and Prisco, Domenico
- Subjects
ATHEROSCLEROSIS risk factors ,THROMBOSIS complications ,CAROTID intima-media thickness ,ANTIPHOSPHOLIPID syndrome ,RISK assessment ,PREGNANCY complications ,DISEASE complications - Published
- 2021
- Full Text
- View/download PDF
37. Comment on: Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis.
- Author
-
Goulielmos, George N and Zervou, Maria I
- Subjects
ATHEROSCLEROSIS risk factors ,THROMBOSIS complications ,ANTIPHOSPHOLIPID syndrome ,RISK assessment ,DISEASE complications ,PREGNANCY - Abstract
The authors discuss a report demonstrating that obstetric antiphospholipid syndrome (APS) is not associated with an increased risk of subclinical atherosclerosis. Topics mentioned include risk of presenting carotid atherosclerotic plaques in women with thrombotic APS, the role of antiphospholipid antibodies in the development of atherosclerosis in the two types of APS, and mechanisms involved in the development of atherosclerosis in APS.
- Published
- 2021
- Full Text
- View/download PDF
38. Comment on: Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus.
- Author
-
Yanxia Chen, Jinlin Liu, Lood, Christian, and Bengtsson, Anders A.
- Subjects
ANTIGENS ,ANTIPHOSPHOLIPID syndrome ,BLOOD platelets ,BLOOD platelet activation ,FLOW cytometry ,SYSTEMIC lupus erythematosus ,DATA analysis - Published
- 2017
- Full Text
- View/download PDF
39. The prevalence of abnormal pulse wave velocity, pulse contour analysis and ankle–brachial index in patients with livedo reticularis: a controlled study.
- Author
-
Sangle, Shirish R., Tanikawa, Akiko, Schreiber, Karen, Zakalka, Marina, and D’Cruz, David P.
- Subjects
STATISTICS ,ANKLE brachial index ,ACADEMIC medical centers ,ANTIPHOSPHOLIPID syndrome ,CHI-squared test ,ARTERIOSCLEROSIS ,RESEARCH funding ,DATA analysis ,SYSTEMIC lupus erythematosus ,PULSE (Heart beat) - Abstract
Objective. To evaluate the prevalence of abnormal pulse wave velocity (PWV), pulse contour analysis (PCA) and abnormal ankle–brachial pressure index (ABPI) in patients with livedo reticularis (livedo) and without livedo.Methods. We recruited 74 patients, of whom 41 had livedo: 16 APS, 9 APS with SLE and 16 with livedo (negative for aPL or lupus). The other group of 33 patients without livedo consisted of 10 APS, 8 APS with SLE and 15 with SLE only. Livedo was diagnosed and confirmed by a dermatologist. PWV was assessed in fasting patients by the Micro Medical PulseTrace analyser using a 4 MHz continuous-wave directional Doppler probe and digital PCA was analysed by Micro Medical PulseTrace by the same operator. Chi-square with Yates’s correction was used for comparing results.Results. The median age of the livedo patients was 46 (29–71) years and of the non-livedo patients was 45 (25–68) years. Abnormal values of PWV in 10/41 (24.40%), ABPI in 4/41 (9.8%) and PCA in 10/41 (24.40%) patients were observed in the livedo group and in the non-livedo group abnormal values of PWV in 1/33 (P ≤ 0.025), ABPI in 0/33 (P = NS) and PCA in 5/33 (P = NS) were observed.Conclusion. Patients with livedo reticularis are more likely to have abnormal PWV, indicating arterial stiffness. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
40. Antithrombotic therapy for pregnancy loss.
- Author
-
de Jong, Paulien G., Goddijn, Mariëtte, and Middeldorp, Saskia
- Subjects
MISCARRIAGE ,ANTICOAGULANTS ,PATHOLOGICAL physiology ,FETAL death ,PREGNANCY complications - Abstract
BACKGROUND Although an association between thrombophilia and pregnancy loss has been observed in many studies, little is known about the pathophysiological mechanisms behind this association. Considering the association between thrombophilia and pregnancy loss, the efficacy of antithrombotic therapy for women with pregnancy loss (with or without thrombophilia) has been studied for the past 30 years. METHODS We performed a comprehensive review of the literature on the strength of the association between thrombophilia and pregnancy loss, the pathophysiological mechanisms and the efficacy of antithrombotic therapy to increase the chance of live birth. RESULTS The association between pregnancy loss and thrombophilia varies according to the type of thrombophilia (e.g. antiphospholipid syndrome versus forms of inherited thrombophilia) and according to the type of pregnancy loss (single versus recurrent pregnancy loss and early versus late pregnancy loss). CONCLUSIONS There are large gaps in knowledge and a lack of evidence for treatment of women with pregnancy loss with thrombophilia. To provide a solid base for clinical practice, further studies on the role of coagulation in reproduction, as well as international collaborations in randomized controlled trials of antithrombotic therapy in women with pregnancy loss, and antiphospholipid syndrome or inherited thrombophilia are urgently needed. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
41. Recurrent miscarriage: do professionals adhere to their guidelines.
- Author
-
van den Boogaard, E., Hermens, R.P.M.G., Franssen, A.M.H.W., Doornbos, J.P.R., Kremer, J.A.M., van der Veen, F., and Goddijn, M.
- Subjects
RECURRENT miscarriage ,KARYOTYPES ,ANTIPHOSPHOLIPID syndrome ,HOSPITAL care quality ,MATERNAL age ,RETROSPECTIVE studies - Abstract
STUDY QUESTION Is the actual care for recurrent miscarriage in clinical practice in accordance with 23 guideline-based quality indicators? SUMMARY ANSWER The accordance of actual care with the guidelines was poor and there is evident room for improvement. WHAT IS KNOWN ALREADY Evidence-based guidelines are important instruments to improve quality of care, but implementation of guidelines is often problematic. STUDY DESIGN, SIZE, DURATION A retrospective cohort study was performed within a 12-month period (2006) in nine departments of Obstetrics and Gynaecology in the Netherlands. PARTICIPANTS, SETTING, METHODS Five hundred and thirty women with recurrent miscarriage were included. Actual care was assessed with 23 guideline-based quality indicators (covering diagnostics, therapy and counselling) by calculating per indicator the percentage of women for whom the indicator was followed. Thereafter we did multilevel analyses, to relate the adherence to the indicator to determinants of women, professionals and hospitals. MAIN RESULTS AND THE ROLE OF CHANCE Homocysteine and antiphospholipid antibodies were determined in 39 and 47%, respectively. Thrombophilia screening (54%) and karyotyping (50%) were offered to women regardless of their underlying risk for inherited thrombophilia or chromosome abnormalities. Higher maternal age at the time of presentation and a lower number of preceding miscarriages were improperly used to decide on diagnostic tests and were both associated with lower guideline adherence by professionals. Professionals with a subspecialization in recurrent miscarriage performed better standard care, i.e. screening for antiphospholipid antibodies and homocysteine, but also showed overuse of diagnostics in women at low risk of inherited thrombophilia. LIMITATIONS, REASONS FOR CAUTION Retrospective cohort study. WIDER IMPLICATIONS OF THE FINDINGS Quality indicators used will enable measurement of quality of care. STUDY FUNDING The study was funded by The Netherlands Organisation for Health Research and Development (ZonMw) (Grant no. 94517005). None of the authors has any conflict of interest to declare. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
42. COVID-19, the wake-up call for implementing sex and gender in cardiovascular disease.
- Author
-
Maas, Angela H E M
- Subjects
SEX factors in disease ,GENDER ,COVID-19 ,CARDIOVASCULAR diseases ,ANTIPHOSPHOLIPID syndrome - Abstract
COVID-19,thewake-upcallforimplementing sexandgenderincardiovasculardisease AngelaH.E.M.Maas * Chair of Women's Cardiac Health Program, Department of Cardiology, Radboud University Medical Center, Geert Grooteplein-Zuid 10, Route 616, 6525GA Nijmegen, The Netherlands Keywords Cardiovascular disease Equality Gender Women Sex differences The COVID-19 pandemic has once again shown that gender diversity, ethnic disparities, lifestyle factors, and socio-economic circumstances are crucial determinants of health. 13 The COVID-19 pandemic has shown that sex and gender matters, and prevention programmes now focus on managing risk factors to lowertherisk. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
43. Comment on: Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion.
- Author
-
Samanta, Joydeep, Naidu, GSRSNK, and Sharma, Aman
- Subjects
THERAPEUTICS ,EVALUATION of medical care ,ANTIPHOSPHOLIPID syndrome ,ANTICOAGULANTS ,SEROCONVERSION ,SYSTEMIC lupus erythematosus - Published
- 2021
- Full Text
- View/download PDF
44. Anticardiolipin antibodies and recurrent early pregnancy loss: a century of equivocal evidence.
- Author
-
Clark, Christine A., Laskin, Carl A., and Spitzer, Karen A.
- Subjects
ANTICARDIOLIPIN antibodies ,PREGNANCY ,ANTIPHOSPHOLIPID syndrome ,PHOSPHOLIPID antibodies ,BLACK swan ,MEDICAL personnel ,PREGNANCY complications - Abstract
In 1987, Nigel Harris cautioned against over-diagnosing the antiphospholipid syndrome (APS). In what was a rather prophetic editorial titled ‘The Syndrome of the Black Swan’, he suggested that while patients with APS do indeed exist, they are probably much more unusual than many medical professionals might like to believe. He expressed concern that the value of studying antiphospholipid antibodies (aPLs) as interesting non-organ specific autoantibodies, would become lost in a ‘sea of over-interpreted and over-reported laboratory and clinical findings’. It is our contention that 25 years later, this prediction has come to pass, particularly with respect to one type of aPL and its relation to a clinical event, namely anticardiolipin antibodies and early recurrent pregnancy loss. In this commentary, we trace the evolution of the current dogma and propose that reevaluation of available data from an alternative perspective results in quite a different understanding, the acceptance of which would necessitate not only a revision of the classification criteria for APS but also the subsequent revision of many diagnoses. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
45. Republished review: Ocular manifestations of the antiphospholipid syndrome.
- Author
-
Utz, Virginia Miraldi and Tang, Johnny
- Subjects
ANTIPHOSPHOLIPID syndrome ,AUTOIMMUNE diseases ,IMMUNOGLOBULINS ,GLYCOPROTEINS ,THROMBOEMBOLISM - Abstract
Antiphospholipid syndrome (APS) is an autoimmune disease characterised by a heterogenous group of antibodies directed against negatively charged phospholipids including antiphospholipid antibodies (aPL), anticardiolipin antibodies (aCL) and β-2 glycoprotein I (ab-2-GP1). The major features of this disorder include arterial and venous thrombosis and recurrent fetal loss. The vasculature of the eye is frequently involved and may be the presenting manifestation. A diagnosis of APS should be considered in a young patients without traditional thromboembolic risk factors presenting with ocular vaso-occlusive disease. Management of these patients involves a team-approach with a haematologist/oncologist or rheumatologist to manage the coagulation status of these patients to prevent further systemic vascular occlusions. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
46. Corrigendum to: Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from EUROAPS registry.
- Author
-
Alijotas-Reig, Jaume, Esteve-Valverde, Enrique, Ferrer-Oliveras, Raquel, Sáez-Comet, Luis, Lefkou, Elmina, Mekinian, Arsène, Belizna, Cristina, Ruffatti, Amelia, Hoxha, Ariela, Tincani, Angela, Nalli, Cecilia, Marozio, Luca, Maina, Aldo, Espinosa, Gerard, Ríos-Garcés, Roberto, Cervera, Ricard, Carolis, Sara De, Monteleone, Giuseppina, Latino, Omar, and Udry, Sebastian
- Subjects
ANTIPHOSPHOLIPID syndrome - Abstract
A correction to the article "Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from EUROAPS registry" is presented.
- Published
- 2021
- Full Text
- View/download PDF
47. The abdominal manifestations of the antiphospholipid syndrome.
- Author
-
Uthman, I. and Khamashta, M.
- Subjects
ANTIPHOSPHOLIPID syndrome ,IMMUNOGLOBULINS ,CIRRHOSIS of the liver ,PHOSPHOLIPID antibodies ,CHRONIC active hepatitis - Abstract
Objectives. To study the abdominal manifestations of the antiphospholipid syndrome (APS). [ABSTRACT FROM PUBLISHER]
- Published
- 2007
- Full Text
- View/download PDF
48. Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome.
- Author
-
Christodoulou, C., Sangle, S., and D'Cruz, D. P.
- Subjects
ANTIPHOSPHOLIPID syndrome ,AUTOIMMUNE diseases ,THROMBOEMBOLISM ,PREGNANCY ,IMMUNOGLOBULINS - Abstract
The antiphospholipid (Hughes) syndrome (APS) is characterized by recurrent arterial or venous thromboembolism, or pregnancy loss, in association with antiphospholipid antibodies. These antibodies may be associated with premature or accelerated atherosclerosis and emerging evidence supports the concept of a vasculopathy in the APS that may lead to arterial stenotic lesions, possibly contributing to vascular occlusions and pregnancy morbidity. [ABSTRACT FROM PUBLISHER]
- Published
- 2007
- Full Text
- View/download PDF
49. Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays.
- Author
-
Tsutsumi, Akito, Hayashi, Taichi, Chino, Yusuke, Mamura, Mizuko, Goto, Daisuke, Matsumoto, Isao, Ito, Satoshi, and Sumida, Takayuki
- Subjects
IMMUNOGLOBULINS ,PROTHROMBIN ,ENZYMES ,IMMUNOASSAY ,ANTIPHOSPHOLIPID syndrome ,PATIENTS - Abstract
Antibodies against prothrombin are detected by enzyme immunoassays (EIA) in sera of patients with antiphospholipid syndrome (APS). However, there are two methods for antiprothrombin EIA; one that uses high binding plates (aPT-A), and another that utilizes phosphatidylserine bound plates (aPS/PT). We aimed to evaluate and compare aPT-A and aPS/PT in a clinical setting. We performed EIA for anti-PT, anti-PS/PT, IgG, and IgM anticardiolipin antibodies (aCL), and IgG β2-glycoprotein I-dependent aCL (aβ2GPI/CL) with serum samples from 139 systemic lupus erythematosus (SLE) patients (16 with history of at least one thrombotic episode) and 148 controls. We observed that: (1) although titers of anti-PT and anti-PS/PT were significantly related with each other ( P < 0.0001, ρ = 0.548), titer of anti-PT and anti-PS/PT differed greatly in some samples; (2) odds ratio and 95% confidence interval for each assay was 3.556 (1.221–10.355) for aPT-A, 4.591 (1.555–15.560) for aPS/PT, 4.204 (1.250–14.148) for IgG aCL, 1.809 (0.354–9.232) for IgM aCL, and 7.246 (2.391–21.966) for aβ2GPI/CL. We conclude that, while all EIA performed in this study except IgM aCL are of potential value in assessing the risk of thrombosis, aPS/PT and aβ2GPI/CL seemed to be highly valuable in clinical practice, and that autoantibodies detected by anti-PT and anti-PS/PT are not completely identical. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
50. The one-stop recurrent miscarriage clinic: an evaluation of its effectiveness and outcome.
- Author
-
Osama M.H. Habayeb and Justin C. Konje
- Subjects
CONCEPTION ,ANTIPHOSPHOLIPID syndrome ,PREGNANCY ,LABOR (Obstetrics) - Abstract
BACKGROUND: Couples with recurrent miscarriages make several visits to specialized clinics for investigations before treatment is offered. Consequently, the interval between receipt of referral and advice to try for a pregnancy is often lengthy. The objectives of this study were to examine the effect of a one-stop clinic on the interval, throughput and the outcome from this clinic. METHODS: The processes for investigation, management and outcomes of 189 couples seen in our Recurrent Miscarriage Clinic (RMC) and their records were reviewed. RESULTS: The one-stop clinic reduced the interval and number of visits by 36% (206.6 to 130.4 days, P<0.001) and by 60% (2.5 to 1, P<0.002) respectively. The prevalence and frequency of aetiological factors were similar in those with two and three or more miscarriages (41% versus 45%, P>0.05). The commonest aetiological factors were thrombophilias (14%) and antiphospholipid syndrome (11%). No cause was identified in 54% of cases. The pregnancy and live birth rates were best in the idiopathic group (75%), those with thrombophilias (64%) and autoimmune antibodies (83%). Older couples had the worse pregnancy rates and outcome. CONCLUSION: A one-stop clinic significantly shortens the interval between referral and initiation of treatment. Investigations should be initiated in women after two consecutive miscarriages. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.